Combining immunotherapy with targeted therapies for better cancer treatment
PROJECT 1: TIME-Based Spatiotemporal Cancer Immunograms Predictive for Immunotherapy-Targeted Therapy Sequential Combinations
This study is looking at how using a mix of immunotherapy and targeted treatments can help kids with cancer do better, especially by trying out a special combination called 'triplet therapy' to see if it can stop cancer from spreading to the brain.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Institute for Systems Biology NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-10916306 on NIH RePORTER |
What this research studies
This research investigates how combining immunotherapy with targeted therapies can improve treatment outcomes for various cancers, particularly in children. The approach focuses on a specific combination therapy known as 'triplet therapy,' which includes anti-PD-L1 and other targeted inhibitors. By analyzing the timing and sequence of these therapies, the research aims to enhance the effectiveness of treatment and reduce the risk of cancer spreading to the brain. The study utilizes advanced models to understand how these therapies interact within the tumor-immune microenvironment.
Who could benefit from this research
Good fit: Ideal candidates for this research are children and young adults with specific types of melanoma or other cancers that may benefit from combination immunotherapy.
Not a fit: Patients with cancers that do not respond to immunotherapy or those who are not eligible for targeted therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments that improve survival rates and quality of life for young patients.
How similar studies have performed: Previous research has shown promising results with similar combination therapies, indicating potential for significant advancements in cancer treatment.
Where this research is happening
Seattle, United States
- Institute for Systems Biology — Seattle, United States (Active)
Researchers
- Principal investigator: Heath, James R. — Institute for Systems Biology
- Study coordinator: Heath, James R.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.